Have a personal or library account? Click to login
Predictors of Progression of Coronary Atherosclerosis after Percutaneous Coronary Intervention Cover

Predictors of Progression of Coronary Atherosclerosis after Percutaneous Coronary Intervention

Open Access
|Sep 2018

References

  1. 1. Bønaa K, Mannsverk J, Wiseth R, et al. - Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242-1252.10.1056/NEJMoa1607991
  2. 2. Kaneko H, Yajima J, Oikawa Y, et al. - Long-term incidence and prognostic factors of progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention. Heart Vessels. 2014;29:437-442.10.1007/s00380-013-0382-6
  3. 3. Park MW, Seung KB, Kim PJ, et al. - Long-term percutaneous coronary intervention rates and associated independent predictors for progression of nonintervened nonculprit coronary lesions. Am J Cardiol. 2009;104:648-652.10.1016/j.amjcard.2009.04.052
  4. 4. Sipahi I, Tuzcu EM, Schoenhagen P, et al. - Effects of normal, prehypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833-838.10.1016/j.jacc.2006.05.045
  5. 5. Borges JC, Lopes N, Soares PR, et al. - Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. J Cardiothorac Surg. 2010;5:91.10.1186/1749-8090-5-91
  6. 6. Boden WE, O’Rourke RA, Teo KK, et al. - Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.10.1056/NEJMoa070829
  7. 7. Ellis SG, Stone GW, Cox DA, et al. - Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: treatment of de novo coronary disease using a single paclitaxel-eluting stent). JACC Cardiovasc Interv. 2009;2:1248-1259.10.1016/j.jcin.2009.10.003
  8. 8. Bangalore S, Kumar S, Fusaro M, et al. - Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixedtreatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873-2891.10.1161/CIRCULATIONAHA.112.097014
  9. 9. Zellweger MJ, Kaiser C, Jeger R, et al. - Coronary artery disease progression late after successful stent implantation. J Am Coll Cardiol. 2012;59:793-799.10.1016/j.jacc.2011.11.024
  10. 10. Alderman EL, Corley SD, Fisher LD, et al. - Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the coronary artery surgery study (CASS). CASS participating investigators and staff. J Am Coll Cardiol. 1993;22:1141-1154.10.1016/0735-1097(93)90429-5
  11. 11. Lichtlen PR, Nikutta P, Jost S, et al. - Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitative coronary angiography. Relation to clinical events and risk factors. The INTACT Study Group. Circulation. 1992;86:828-838.10.1161/01.CIR.86.3.828
  12. 12. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable Artery disease Investigators - Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.10.1016/S0140-6736(03)14286-9
  13. 13. Gude D - Angiotensin-converting enzyme inhibitors in lipid metabolism and atherosclerosis: An ace up the sleeve? J Sci Soc. 2014;41;59-60.10.4103/0974-5009.126762
DOI: https://doi.org/10.2478/amma-2018-0020 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 103 - 107
Submitted on: Jul 23, 2018
|
Accepted on: Aug 28, 2018
|
Published on: Sep 25, 2018
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2018 Violeta Dinesch, Mihail Dinesch, Ileana Voichita Sirbu, Cosmin Macarie, Bogdan Vasile Halatiu, Mircea Buruian, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.